换一批摘要Pancreatic ductal adenocarcinoma (PDAC) remains still one of the most lethal tumor entities and will be the second leading cause of cancer-related death within the next ten years for both male and female patients. This frustrating development is mainly ex- plained by an increasing incidence and still limited therapeutical success [ 1 , 2 ]. Only about 15％-20％ of all patients diagnosed with PDAC qualify for upfront surgery, while in the remaining patients, locally advanced or metastatic tumor stages are found at diagno- sis, the largest proportion of these patients presenting with stage IV tumors [3] .
更多相关知识
发布时间
2023-04-27（万方平台首次上网日期，不代表论文的发表时间）
- 浏览6
- 被引0
- 下载0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
